Skip to search formSkip to main contentSkip to account menu

VTX-2337

Known as: TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 
A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzazepines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
In vitro metabolic profiles of motolimod by using liquid chromatography tandem mass spectrometry: Metabolic stability, metabolite characterization and species comparison
2019
2019
Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Highly Cited
2018
Highly Cited
2018
TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG
Toll-like receptors (TLRs) are nucleic acid–sensing receptors and have been implicated in mediating pain and itch. Here we report… 
Highly Cited
2016
Highly Cited
2016
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an… 
Highly Cited
2014
Highly Cited
2014
A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
Purpose: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD… 
2014
2014
Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head…
TPS3123 Background: The potential for synergy between cytotoxic and immunologic agents is an exciting area of exploration in… 
2013
2013
VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group.
3077 Background: Given the absence of clear molecular drivers in high-grade serous ovarian cancer, targeting the tumor micro… 
2013
2013
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and… 
Highly Cited
2011
Highly Cited
2011
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… 
2011
2011
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
2537 Background: Toll-like receptors (TLRs) have emerged as attractive targets for anti-cancer immunotherapies. VTX-2337 is a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)